The good news is that numerous states have enacted legislation that allows for the use of CBD. Just four states (Idaho, South Dakota, Nebraska, and Kansas) forbid any access to marijuana. Ten states and Washington, D.C., currently allow for both medical and recreational use of cannabis, including CBD products. The other 36 states allow for the use of medical cannabis in some form, though some of these relegate this to CBD oil only.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. There is absolutely no assurance that any statement contained or cited in an article touching on medical matters is true, correct, precise, or up-to-date. The overwhelming majority of such articles are written, in part or in whole, by nonprofessionals.
Psychoactive – Any chemical substance that can enter the brain from the bloodstream and directly affect the central nervous system is considered psychoactive. Many psychoactive substances have medical applications (such as anesthetics, psychiatric drugs, etc.), but some of these substances are used solely for recreation, causing dangerous side effects and addiction.
Until relatively recently (1980s), scientists believed that CBD was a natural precursor to the formation of THC, and since THC was a strictly controlled substance back then (it still is), it only followed that CBD should be equally strictly regulated. However, CBD is actually unrelated to the chemical chain that results in THC. They share some characteristics but are created via different paths. Again, unlike THC, CBD is considered a legal cannabinoid and is safe to consume in any amount and concentration.
This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
In September 2018, following its approval by the FDA for rare types of childhood epilepsy, Epidiolex was rescheduled (by the Drug Enforcement Administration) as a Schedule V drug to allow for its prescription use. This allows GW Pharmaceuticals to sell Epidiolex, but it does not apply broadly and all other CBD-containing products remain Schedule I drugs. Epidiolex still requires rescheduling in some states before it can be prescribed in those states.